Gan & Lee Pharmaceuticals. (603087.SS)
CNY 45.54
(0.35%)
CNY 45.54
(0.35%)
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2023 | 860.5 Million CNY | 32.66% |
| 2022 | 648.64 Million CNY | -0.41% |
| 2021 | 651.32 Million CNY | 31.99% |
| 2020 | 493.48 Million CNY | 4.7% |
| 2019 | 471.34 Million CNY | 21.13% |
| 2018 | 389.13 Million CNY | 83.28% |
| 2017 | 212.31 Million CNY | 45.45% |
| 2016 | 145.97 Million CNY | 18.5% |
| 2015 | 123.18 Million CNY | 54.18% |
| 2014 | 79.89 Million CNY | -1.13% |
| 2013 | 80.81 Million CNY | 0.0% |
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2024 Q1 | 932.04 Million CNY | 8.31% |
| 2024 Q3 | 1.02 Billion CNY | 8.19% |
| 2024 Q2 | 950.33 Million CNY | 1.96% |
| 2023 FY | 860.5 Million CNY | 32.66% |
| 2023 Q1 | 688.68 Million CNY | 6.17% |
| 2023 Q3 | 858.84 Million CNY | 14.6% |
| 2023 Q4 | 860.5 Million CNY | 0.19% |
| 2023 Q2 | 749.45 Million CNY | 8.82% |
| 2022 Q3 | 668.23 Million CNY | -8.8% |
| 2022 Q1 | 732.29 Million CNY | 12.43% |
| 2022 FY | 648.64 Million CNY | -0.41% |
| 2022 Q4 | 648.64 Million CNY | -2.93% |
| 2022 Q2 | 732.71 Million CNY | 0.06% |
| 2021 Q1 | 560.44 Million CNY | 13.57% |
| 2021 Q3 | 575.54 Million CNY | -0.44% |
| 2021 Q2 | 578.06 Million CNY | 3.14% |
| 2021 Q4 | 651.32 Million CNY | 13.17% |
| 2021 FY | 651.32 Million CNY | 31.99% |
| 2020 Q3 | 525.58 Million CNY | -0.43% |
| 2020 FY | 493.48 Million CNY | 4.7% |
| 2020 Q1 | 501.54 Million CNY | 6.41% |
| 2020 Q4 | 493.48 Million CNY | -6.11% |
| 2020 Q2 | 527.86 Million CNY | 5.25% |
| 2019 FY | 471.34 Million CNY | 21.13% |
| 2019 Q1 | - CNY | 0.0% |
| 2019 Q4 | 471.34 Million CNY | 0.0% |
| 2018 FY | 389.13 Million CNY | 83.28% |
| 2017 Q1 | 188.04 Million CNY | 0.0% |
| 2017 FY | 212.31 Million CNY | 45.45% |
| 2017 Q4 | 212.31 Million CNY | 0.0% |
| 2017 Q2 | 188.04 Million CNY | 0.0% |
| 2016 FY | 145.97 Million CNY | 18.5% |
| 2015 FY | 123.18 Million CNY | 54.18% |
| 2014 FY | 79.89 Million CNY | -1.13% |
| 2013 FY | 80.81 Million CNY | 0.0% |